AU2925789A - Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection - Google Patents

Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection

Info

Publication number
AU2925789A
AU2925789A AU29257/89A AU2925789A AU2925789A AU 2925789 A AU2925789 A AU 2925789A AU 29257/89 A AU29257/89 A AU 29257/89A AU 2925789 A AU2925789 A AU 2925789A AU 2925789 A AU2925789 A AU 2925789A
Authority
AU
Australia
Prior art keywords
cells
hiv infection
adoptive immunotherapy
lymphokine activation
lymphokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29257/89A
Inventor
James C. Sharp
Abdul Jabear Sultan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BROWNING S CLINICAL PATHOLOGY
Original Assignee
BROWNING S CLINICAL PATHOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878729410A external-priority patent/GB8729410D0/en
Priority claimed from GB888817082A external-priority patent/GB8817082D0/en
Priority claimed from GB888823895A external-priority patent/GB8823895D0/en
Priority claimed from GB888823896A external-priority patent/GB8823896D0/en
Priority claimed from GB888823897A external-priority patent/GB8823897D0/en
Application filed by BROWNING S CLINICAL PATHOLOGY filed Critical BROWNING S CLINICAL PATHOLOGY
Publication of AU2925789A publication Critical patent/AU2925789A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU29257/89A 1987-12-17 1988-12-19 Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection Abandoned AU2925789A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB878729410A GB8729410D0 (en) 1987-12-17 1987-12-17 Method for production of lymphokine activated killer(lak)cells & lak cells so produced
GB8729410 1987-12-17
GB888817082A GB8817082D0 (en) 1988-07-18 1988-07-18 Method for production of lymphokine activated killer(lak)cells so produced & their use
GB8817082 1988-07-18
GB8823896 1988-10-12
GB888823895A GB8823895D0 (en) 1988-10-12 1988-10-12 Lymphokine activation of lymphocytes
GB8823897 1988-10-12
GB888823896A GB8823896D0 (en) 1988-10-12 1988-10-12 Improvements relating to lymphokine activated cells
GB888823897A GB8823897D0 (en) 1988-10-12 1988-10-12 Process for stimulating & activating lymphocytes
GB8823895 1988-10-12

Publications (1)

Publication Number Publication Date
AU2925789A true AU2925789A (en) 1989-07-19

Family

ID=27516781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29257/89A Abandoned AU2925789A (en) 1987-12-17 1988-12-19 Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection

Country Status (2)

Country Link
AU (1) AU2925789A (en)
WO (1) WO1989005657A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147633T1 (en) * 1988-10-27 1997-02-15 Univ Minnesota IMMUNE AID FROM LIPOSOMES CONTAINING LYMPHOKINE IL -2
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
EP0578740A4 (en) * 1991-04-05 1995-12-20 Univ Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
DE4228389C2 (en) * 1992-08-26 1994-07-21 Kuebler Gmbh Dr Collection and cultivation of transformed cells
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
EP1401495A4 (en) * 2001-06-01 2005-11-23 Xcyte Therapies Inc T cell induced tissue repair and regeneration
WO2005051927A1 (en) * 2003-11-26 2005-06-09 Kureha Corporation Method of culturing cd4-positive t cells via stimulation culture of hiv-1-infected pheripheral monocytes and hiv-1 growth inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2106935B (en) * 1981-10-01 1985-01-30 Otsuka Pharma Co Ltd Cancer cell-combatting lymphocytes process for the production thereof and anticancer agents containing said lymphocytes
ES8800981A1 (en) * 1985-06-28 1987-12-01 Univ Minnesota Process and composition for treatment of cancer and non-malignant tumors.
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
EP0302894B1 (en) * 1986-04-28 1992-11-19 Endotronics Inc. Method of culturing leukocytes
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
EP0257962A3 (en) * 1986-08-29 1989-05-24 Becton, Dickinson and Company Method for treatment of peripheral blood to improve lymphokine activated killer immunotherapy
EP0260714B1 (en) * 1986-09-19 1994-06-29 Oncogen Limited Partnership The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
WO1988007077A1 (en) * 1987-03-11 1988-09-22 The Children's Hospital, Incorporated Method for the generation of antigen-specific t cell lines and therapeutic use thereof

Also Published As

Publication number Publication date
WO1989005657A1 (en) 1989-06-29

Similar Documents

Publication Publication Date Title
AU589732B2 (en) Process for the preparation of 2-oxo-1,3-dioxolanes
AU7246687A (en) 5-arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and processes for the preparation thereof and medicaments containing them
AU566321B1 (en) N,n1-dihalo-2-imidazolidinones
AU607944B2 (en) Cell growth rate determination
AU7469787A (en) Process for the genetic modification of yeast
AU2828989A (en) Long-life membrane electrode for non-ionic species
AU1435588A (en) Blood centrifugation cell
AU617088B2 (en) Peptides involved in the pathogenesis of hiv infection
AU6150686A (en) Process for the preparation of 2-oxo-1,3-dioxolanes
AU590699B2 (en) Radial arm saw
AU7549387A (en) High pressure, high temperature polymerization of ethylene
AU2925789A (en) Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
AU1365588A (en) Thin film membrane, enzyme reactors
AU7374387A (en) 2-hydrazono-4,6-dinitrobenthiazolones
AU2179688A (en) Recombinant eukaryotic cells production interleukin-2, process and vectors for their preparation and process for the preparation of interleukin-2
AU2458988A (en) The preparation, by genetic manipulation, of anticoagulative protein pp4
AU7646087A (en) Covalent membranes
AU1574188A (en) T-cell membrane protein
AU1959488A (en) (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonin
AU1004588A (en) Solution ibuprofen complexes, compositions and processes for preparing same
AU3447589A (en) Process for manufacture of plates, especially for construction use
AU1569988A (en) New aminophenylethylamine derivatives, processes for their preparation and their use as yield promoters
AU6940087A (en) Covalent membranes
AU8178987A (en) Orientable support
AU5861590A (en) Flat, conformable, biomedical electrode